Review of non-surgical treatment options for Peyronie's Disease

被引:0
作者
S M Larsen
L A Levine
机构
[1] Rush University Medical Center,Department of Urology
来源
International Journal of Impotence Research | 2012年 / 24卷
关键词
Peyronie's disease; traction; intralesional injection; oral therapy; non-surgical;
D O I
暂无
中图分类号
学科分类号
摘要
Non-surgical treatment of Peyronie's disease (PD) has come a long way since it was first described in 1743. A myriad of treatment options are currently available, including oral, intralesional and external energy therapies. The purpose of this article is to review the contemporary literature on non-surgical therapies for PD, and where possible, focus on randomized, placebo-controlled trials, as well as review the latest guidelines for the management of PD from the International Committee on Sexual Medicine, which conveyed its findings in July 2009. At this time, it appears that a combination of oral agents and/or intralesional injection with traction therapy may provide a synergy between the chemical effects of the drugs and the mechanical effects of traction. Until a reliable treatment emerges, it does appear that some of the non-surgical treatments discussed can be used to stabilize the scarring process and may result in some reduction of deformity with improved sexual function.
引用
收藏
页码:1 / 10
页数:9
相关论文
共 313 条
  • [1] de La Peyronie F(1743)Sur quelques obstaclesqui sópposent à l'éjaculation nautrelle de la semence Mem Acad Royale Chir 1 337-342
  • [2] El-Sakka AI(1997)An animal model of Peyronie's like condition associated with an increase of transforming growth factor beta mRNA and protein expression J Urol 158 2284-2290
  • [3] Hassoba HM(1997)Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression J Urol 158 1391-1394
  • [4] Chui RM(2002)Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses Int J Impot Res 14 397-405
  • [5] Bhatnagar RS(1996)Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology J Urol 156 1330-1334
  • [6] Dahiya R(1997)Immunologic findings in Peyronie's disease: a controlled study Urology 50 764-768
  • [7] Lue TF(2008)Profibrotic role of myostatin in Peyronie's disease J Sex Med 5 1607-1622
  • [8] El-Sakka AI(2009)IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease J Sex Med 6 1284-1296
  • [9] Hassoba HM(2008)Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts J Urol 179 2447-2455
  • [10] Pillarisetty RJ(2007)Defining the clinical characteristics of Peyronie's disease in young men J Sex Med 4 485-490